BRPI0500520A - uso de agentes flavorizantes aromáticos de alto ponto de fusão como agentes solubilizantes ou inibidores de cristalização em composições farmacêuticas - Google Patents
uso de agentes flavorizantes aromáticos de alto ponto de fusão como agentes solubilizantes ou inibidores de cristalização em composições farmacêuticasInfo
- Publication number
- BRPI0500520A BRPI0500520A BRPI0500520-5A BRPI0500520A BRPI0500520A BR PI0500520 A BRPI0500520 A BR PI0500520A BR PI0500520 A BRPI0500520 A BR PI0500520A BR PI0500520 A BRPI0500520 A BR PI0500520A
- Authority
- BR
- Brazil
- Prior art keywords
- pharmaceutical compositions
- agents
- crystallization inhibitors
- solubilizing agents
- high melting
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
Abstract
"USO DE AGENTES FLAVORIZANTES AROMáTICOS DE ALTO PONTO DE FUSãO COMO AGENTES SOLUBILIZANTES OU INIBIDORES DE CRISTALIZAçãO EM COMPOSIçõES FARMACêUTICAS". A presente invenção consiste de processos de manufatura de composições farmacêuticas caracterizadas pelo uso de compostos flavorizantes aromáticos com ponto de fusão superior a 20<198>C como agentes solubilizantes ou inibidores da cristalização. Complementarmente, a presente invenção também compreende composições farmacêuticas caracterizadas por conterem compostos flavorizantes aromáticos com ponto de fusão superior a 20 <198>C como agentes solubilizantes ou inibidores da cristalização.
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BRPI0500520-5A BRPI0500520A (pt) | 2005-02-16 | 2005-02-16 | uso de agentes flavorizantes aromáticos de alto ponto de fusão como agentes solubilizantes ou inibidores de cristalização em composições farmacêuticas |
ARP060100561A AR053681A1 (es) | 2005-02-16 | 2006-02-16 | Uso de agentes saborizantes aromaticos de alto punto de fusion como agentes solubilicantes o inhibidores de la cristalizacion en composiciones farmaceuticas |
PCT/BR2006/000024 WO2006086862A1 (en) | 2005-02-16 | 2006-02-16 | Use of aromatic flavouring agents with high melting point as solubilizing agents |
EP06705070A EP1853319A4 (en) | 2005-02-16 | 2006-02-16 | USE OF HIGH MELT AROMATIC FLAVORS AS SOLUBILIZING AGENTS |
US11/889,764 US20080064675A1 (en) | 2005-02-16 | 2007-08-16 | Use of Aromatic flavoring agents with high melting point as solubilizing agents |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BRPI0500520-5A BRPI0500520A (pt) | 2005-02-16 | 2005-02-16 | uso de agentes flavorizantes aromáticos de alto ponto de fusão como agentes solubilizantes ou inibidores de cristalização em composições farmacêuticas |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0500520A true BRPI0500520A (pt) | 2006-09-26 |
Family
ID=36916127
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0500520-5A BRPI0500520A (pt) | 2005-02-16 | 2005-02-16 | uso de agentes flavorizantes aromáticos de alto ponto de fusão como agentes solubilizantes ou inibidores de cristalização em composições farmacêuticas |
Country Status (5)
Country | Link |
---|---|
US (1) | US20080064675A1 (pt) |
EP (1) | EP1853319A4 (pt) |
AR (1) | AR053681A1 (pt) |
BR (1) | BRPI0500520A (pt) |
WO (1) | WO2006086862A1 (pt) |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1132518A (en) * | 1965-02-18 | 1968-11-06 | Richardson Merrell Inc | Medicinal composition |
DE3339236A1 (de) * | 1983-10-28 | 1985-05-09 | Bayer Ag | Arzneimittelzubereitung |
US5665386A (en) * | 1995-06-07 | 1997-09-09 | Avmax, Inc. | Use of essential oils to increase bioavailability of oral pharmaceutical compounds |
CN1174741C (zh) * | 1999-09-21 | 2004-11-10 | Rtp药品公司 | 生物活性物质的表面改性微粒组合物 |
WO2002010125A1 (en) * | 2000-07-27 | 2002-02-07 | Teva Pharmaceutical Industries Ltd. | Crystalline and pure modafinil, and process of preparing the same |
US6489363B2 (en) * | 2000-10-11 | 2002-12-03 | Cephalon, Inc. | Pharmaceutical solutions of modafinil compounds |
WO2003070168A2 (en) * | 2002-02-18 | 2003-08-28 | Michigan State University | Method of treating inflammation and inflammation-related pain |
US20040116532A1 (en) * | 2002-09-13 | 2004-06-17 | Craig Heacock | Pharmaceutical formulations of modafinil |
BRPI0501120A (pt) * | 2005-02-18 | 2006-10-03 | Henry Jun Suzuki | composições farmacêuticas orais e parenterais contendo altas concentrações de agentes solubilizantes aromáticos |
-
2005
- 2005-02-16 BR BRPI0500520-5A patent/BRPI0500520A/pt not_active IP Right Cessation
-
2006
- 2006-02-16 AR ARP060100561A patent/AR053681A1/es not_active Application Discontinuation
- 2006-02-16 WO PCT/BR2006/000024 patent/WO2006086862A1/en active Application Filing
- 2006-02-16 EP EP06705070A patent/EP1853319A4/en not_active Withdrawn
-
2007
- 2007-08-16 US US11/889,764 patent/US20080064675A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20080064675A1 (en) | 2008-03-13 |
AR053681A1 (es) | 2007-05-16 |
WO2006086862A1 (en) | 2006-08-24 |
EP1853319A1 (en) | 2007-11-14 |
EP1853319A4 (en) | 2012-01-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2007148185A3 (en) | Substituted 3 -amino- pyrrolidino-4 -lactams as dpp inhibitors | |
WO2007098270A3 (en) | Co-crystals comprising vx-950 and pharmaceutical compositions comprising the same | |
WO2007076260A3 (en) | Farnesoid x receptor agonists | |
DK1881985T3 (da) | Vandfrie krystalliske former af N-Y1-(2-ethoxyethyl)-5-(N-ethyl-N-methylamino)-7-(4-methylpyridin-2-yl-amino)-1H-pyrazolo[4,3-D]pyrimidin-3-carbonyl¨methansulfonamid | |
WO2008013838A3 (en) | Pyridizinone derivatives | |
WO2007067506A3 (en) | 2-pyrimidinyl pyrazolopyridine erbb kinase inhibitors | |
SE0101675D0 (sv) | Novel composition | |
WO2006120563A3 (en) | Antibacterial agents | |
CY1109916T1 (el) | Βενζιμιδαζολο-θειοφαινικες ενωσεις ως plk αναστολεις | |
NO20075298L (no) | Novel thiophene derivatives as sphingosine-1-phosphate-1 receptor agonists | |
BRPI0818672A2 (pt) | 2'-fluor-2'-desoxitetra-hidrouridinas como inibidores da citidina desaminase | |
WO2007079199A3 (en) | Substituted bis-amide metalloprotease inhibitors | |
WO2007016674A3 (en) | 2-aminoaryl pyridines as protein kinases inhibitors | |
TNSN07222A1 (en) | Nematicidal compositions | |
WO2006088803A3 (en) | Polypeptides from staphylococcus aureus and methods of use | |
WO2008022286A3 (en) | Small molecule inhibitors of kynurenine-3-monooxygenase | |
WO2007065595A3 (en) | Xanthine derivatives, processes for preparing them and their uses | |
WO2007056625A3 (en) | Thienopyridine b-raf kinase inhibitors | |
WO2007070562A3 (en) | Non-hygroscopic compositions of enterostatin | |
WO2007120333A3 (en) | Tetracyclic kinase inhibitors | |
CL2004001085A1 (es) | Compuestos derivados de quinolil propil piperidina, procedimiento de preparacion; compuesto intermediario; composicion farmaceutica, utiles como agentes microbianos. | |
WO2007087026A3 (en) | Solid-state form of amg 706 and pharmaceutical compositions thereof | |
WO2008045663A3 (en) | Aryl-substituted heterocyclic pde4 inhibitors as antiinflammatory agents | |
EP1944027A4 (en) | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OR PREVENTION OF NEPHRITIS AND METHOD FOR PRODUCING THE SAME | |
WO2007070563A3 (en) | Stable solid forms of enterostatin |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application fees: application dismissed [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 8A ANUIDADE(S). |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2204 DE 02/04/2013. |